Global Oocyte Cryopreservation Market
Global Oocyte Cryopreservation Market

Oocyte Cryopreservation Comprehensive Study by Type (Slow-cooling Method, Flash-freezing Process (Vitrification)), Application (25-30-Year-Old Female, 30-35-Year-Old Female, 35-40-Year-Old Female, Others), Component (Cryopreservation Media, Cryopreservation Storage Devices (Dewars, Cryogenic Liquid Cylinders, Cryogenic Storage Tanks, and Storage Container), Consumables & Accessories, Cryo-Shipping), End User (Biobanks, IVF & Fertility Clinics, Research & Academic Institutes, Cryo-shipping/couriers, Cryo Monitoring /Inventory Management) Players and Region - Global Market Outlook to 2026

Oocyte Cryopreservation Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Jan 2021 Edition 201 Pages 216 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Global Oocyte Cryopreservation Market Overview:
Oocyte cryopreservation is a promising adjunct to human-assisted reproductive technology. Slow rate freezing has been the cryopreservation standard for the storage of sperm, embryos, and, subsequently, oocytes. Moreover, many studies indicated that acceptable oocyte survival, in vitro fertilization, normal embryos, and adequate blastocyst development can be achieved with oocyte cryopreservation, this has projected the growth of the global oocyte cryopreservation market in the forecast period. Some of the players profiled in the study are Anova Fertility (Canada), Manchester Fertility (United Kingdom), CCRM IVF (United States), CREATE Fertility (United Kingdom), Extend Fertility (United States), Kindbody (United States), HRC Fertility (United States), London Women's Clinic (United Kingdom), IVF Australia (Australia) and Prelude Fertility (United States).

On the basis of geography, the market of Oocyte Cryopreservation has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Component, the sub-segment i.e. Cryopreservation Media will boost the Oocyte Cryopreservation market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End User, the sub-segment i.e. Biobanks will boost the Oocyte Cryopreservation market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Growth Drivers
  • Increasing Number of Egg, Sperm, or Embryo Donors
  • Raising Awareness about the Procedure among Individuals
  • Growing Numbers of Women Undergo Oocyte Cryopreservation for Both Medical and Social Reasons

Influencing Trend
  • Advancements in Freezing technology are Likely to Increase the Use of Donor Eggs, Sperm, or Embryo for Fertility Treatment

Restraints
  • High Cost Associated with Oocyte Cryopreservation

Opportunities
  • Increased Emphasis on R&D Investments and Drug Discovery, Several Small Companies have Resorted to Outsourcing their Drug Discovery Process to Subcontract Laboratories

Challenges
  • Ice Formation and Damage to Oocyte Cryopreservation
  • Low Awareness about Cryogenic Offerings in Developing Countries and Rural Areas




The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies.

Target Audience:
Oocyte Cryopreservation Providers, Research Organizations and Consulting Companies, Potential Technology Investors, Regulatory & Government Bodies, Downstream Vendors, End Users and Others

Major Objectives Focused through this Study
• To define, describe, and forecast the Global Oocyte Cryopreservation market on the basis of product [Slow-cooling Method and Flash-freezing Process (Vitrification)] , application [25-30-Year-Old Female, 30-35-Year-Old Female, 35-40-Year-Old Female and Others], key regions and end user
• To provide in-depth information regarding major influencing factors affecting the growth of the market (trends, drivers, restraints, opportunities, and industry-centric and regional challenges)
• To strategically analyse the micro-markets and important business segments with respect to individual growth drivers , market trends and potential, and historical contributions to the total market
• Identifying the opportunities in the market for key stakeholders and detailing the competitive landscape for market leaders
• To provide market size for various segments of the Oocyte Cryopreservation market with respect to major geographies, namely, South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico)
• To strategically profile the key players and analyzing their market shares and core competencies in the Oocyte Cryopreservation industry
• To track key developments such as product launches, expansions, agreements, partnerships, mergers & acquisitions, and R&D activities that are key factors in shaping the market

Available Customization:
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**. Additionally, the Players which are also part of the research are Reproductive Biology Associates (United States), Virtus Health (Australia), Mayo Clinic (United States), Pacific Fertility Center-Los Angeles (PFCLA) (United States), Monash IVF (Australia), Shady Grove Fertility (United States), Melbourne IVF (Australia) and San Diego Fertility Center (SDFC) (United States).
** Confirmation on availability of data would be informed prior purchase

While framing the research framework, major and emerging players operating in the Oocyte Cryopreservation market in various regions have been profiled, and their offerings, geographic footprints, and distribution/sales channels have been analysed through in-depth discussions. The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.
Report Objectives / Segmentation Covered
By Type
  • Slow-cooling Method
  • Flash-freezing Process (Vitrification)
By Application
  • 25-30-Year-Old Female
  • 30-35-Year-Old Female
  • 35-40-Year-Old Female
  • Others
By Component
  • Cryopreservation Media
  • Cryopreservation Storage Devices (Dewars, Cryogenic Liquid Cylinders, Cryogenic Storage Tanks, and Storage Container)
  • Consumables & Accessories
  • Cryo-Shipping

By End User
  • Biobanks
  • IVF & Fertility Clinics
  • Research & Academic Institutes
  • Cryo-shipping/couriers
  • Cryo Monitoring /Inventory Management

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Number of Egg, Sperm, or Embryo Donors
      • 3.2.2. Raising Awareness about the Procedure among Individuals
      • 3.2.3. Growing Numbers of Women Undergo Oocyte Cryopreservation for Both Medical and Social Reasons
    • 3.3. Market Challenges
      • 3.3.1. Ice Formation and Damage to Oocyte Cryopreservation
      • 3.3.2. Low Awareness about Cryogenic Offerings in Developing Countries and Rural Areas
    • 3.4. Market Trends
      • 3.4.1. Advancements in Freezing technology are Likely to Increase the Use of Donor Eggs, Sperm, or Embryo for Fertility Treatment
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Oocyte Cryopreservation, by Type, Application, Component, End User and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Oocyte Cryopreservation (Value)
      • 5.2.1. Global Oocyte Cryopreservation by: Type (Value)
        • 5.2.1.1. Slow-cooling Method
        • 5.2.1.2. Flash-freezing Process (Vitrification)
      • 5.2.2. Global Oocyte Cryopreservation by: Application (Value)
        • 5.2.2.1. 25-30-Year-Old Female
        • 5.2.2.2. 30-35-Year-Old Female
        • 5.2.2.3. 35-40-Year-Old Female
        • 5.2.2.4. Others
      • 5.2.3. Global Oocyte Cryopreservation by: Component (Value)
        • 5.2.3.1. Cryopreservation Media
        • 5.2.3.2. Cryopreservation Storage Devices (Dewars, Cryogenic Liquid Cylinders, Cryogenic Storage Tanks, and Storage Container)
        • 5.2.3.3. Consumables & Accessories
        • 5.2.3.4. Cryo-Shipping
      • 5.2.4. Global Oocyte Cryopreservation by: End User (Value)
        • 5.2.4.1. Biobanks
        • 5.2.4.2. IVF & Fertility Clinics
        • 5.2.4.3. Research & Academic Institutes
        • 5.2.4.4. Cryo-shipping/couriers
        • 5.2.4.5. Cryo Monitoring /Inventory Management
      • 5.2.5. Global Oocyte Cryopreservation Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Oocyte Cryopreservation: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Anova Fertility (Canada)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Manchester Fertility (United Kingdom)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. CCRM IVF (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. CREATE Fertility (United Kingdom)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Extend Fertility (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Kindbody (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. HRC Fertility (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. London Women's Clinic (United Kingdom)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. IVF Australia (Australia)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Prelude Fertility (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Oocyte Cryopreservation Sale, by Type, Application, Component, End User and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Oocyte Cryopreservation (Value)
      • 7.2.1. Global Oocyte Cryopreservation by: Type (Value)
        • 7.2.1.1. Slow-cooling Method
        • 7.2.1.2. Flash-freezing Process (Vitrification)
      • 7.2.2. Global Oocyte Cryopreservation by: Application (Value)
        • 7.2.2.1. 25-30-Year-Old Female
        • 7.2.2.2. 30-35-Year-Old Female
        • 7.2.2.3. 35-40-Year-Old Female
        • 7.2.2.4. Others
      • 7.2.3. Global Oocyte Cryopreservation by: Component (Value)
        • 7.2.3.1. Cryopreservation Media
        • 7.2.3.2. Cryopreservation Storage Devices (Dewars, Cryogenic Liquid Cylinders, Cryogenic Storage Tanks, and Storage Container)
        • 7.2.3.3. Consumables & Accessories
        • 7.2.3.4. Cryo-Shipping
      • 7.2.4. Global Oocyte Cryopreservation by: End User (Value)
        • 7.2.4.1. Biobanks
        • 7.2.4.2. IVF & Fertility Clinics
        • 7.2.4.3. Research & Academic Institutes
        • 7.2.4.4. Cryo-shipping/couriers
        • 7.2.4.5. Cryo Monitoring /Inventory Management
      • 7.2.5. Global Oocyte Cryopreservation Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Oocyte Cryopreservation: by Type(USD Million)
  • Table 2. Oocyte Cryopreservation Slow-cooling Method , by Region USD Million (2015-2020)
  • Table 3. Oocyte Cryopreservation Flash-freezing Process (Vitrification) , by Region USD Million (2015-2020)
  • Table 4. Oocyte Cryopreservation: by Application(USD Million)
  • Table 5. Oocyte Cryopreservation 25-30-Year-Old Female , by Region USD Million (2015-2020)
  • Table 6. Oocyte Cryopreservation 30-35-Year-Old Female , by Region USD Million (2015-2020)
  • Table 7. Oocyte Cryopreservation 35-40-Year-Old Female , by Region USD Million (2015-2020)
  • Table 8. Oocyte Cryopreservation Others , by Region USD Million (2015-2020)
  • Table 9. Oocyte Cryopreservation: by Component(USD Million)
  • Table 10. Oocyte Cryopreservation Cryopreservation Media , by Region USD Million (2015-2020)
  • Table 11. Oocyte Cryopreservation Cryopreservation Storage Devices (Dewars, Cryogenic Liquid Cylinders, Cryogenic Storage Tanks, and Storage Container) , by Region USD Million (2015-2020)
  • Table 12. Oocyte Cryopreservation Consumables & Accessories , by Region USD Million (2015-2020)
  • Table 13. Oocyte Cryopreservation Cryo-Shipping , by Region USD Million (2015-2020)
  • Table 14. Oocyte Cryopreservation: by End User(USD Million)
  • Table 15. Oocyte Cryopreservation Biobanks , by Region USD Million (2015-2020)
  • Table 16. Oocyte Cryopreservation IVF & Fertility Clinics , by Region USD Million (2015-2020)
  • Table 17. Oocyte Cryopreservation Research & Academic Institutes , by Region USD Million (2015-2020)
  • Table 18. Oocyte Cryopreservation Cryo-shipping/couriers , by Region USD Million (2015-2020)
  • Table 19. Oocyte Cryopreservation Cryo Monitoring /Inventory Management , by Region USD Million (2015-2020)
  • Table 20. South America Oocyte Cryopreservation, by Country USD Million (2015-2020)
  • Table 21. South America Oocyte Cryopreservation, by Type USD Million (2015-2020)
  • Table 22. South America Oocyte Cryopreservation, by Application USD Million (2015-2020)
  • Table 23. South America Oocyte Cryopreservation, by Component USD Million (2015-2020)
  • Table 24. South America Oocyte Cryopreservation, by End User USD Million (2015-2020)
  • Table 25. Brazil Oocyte Cryopreservation, by Type USD Million (2015-2020)
  • Table 26. Brazil Oocyte Cryopreservation, by Application USD Million (2015-2020)
  • Table 27. Brazil Oocyte Cryopreservation, by Component USD Million (2015-2020)
  • Table 28. Brazil Oocyte Cryopreservation, by End User USD Million (2015-2020)
  • Table 29. Argentina Oocyte Cryopreservation, by Type USD Million (2015-2020)
  • Table 30. Argentina Oocyte Cryopreservation, by Application USD Million (2015-2020)
  • Table 31. Argentina Oocyte Cryopreservation, by Component USD Million (2015-2020)
  • Table 32. Argentina Oocyte Cryopreservation, by End User USD Million (2015-2020)
  • Table 33. Rest of South America Oocyte Cryopreservation, by Type USD Million (2015-2020)
  • Table 34. Rest of South America Oocyte Cryopreservation, by Application USD Million (2015-2020)
  • Table 35. Rest of South America Oocyte Cryopreservation, by Component USD Million (2015-2020)
  • Table 36. Rest of South America Oocyte Cryopreservation, by End User USD Million (2015-2020)
  • Table 37. Asia Pacific Oocyte Cryopreservation, by Country USD Million (2015-2020)
  • Table 38. Asia Pacific Oocyte Cryopreservation, by Type USD Million (2015-2020)
  • Table 39. Asia Pacific Oocyte Cryopreservation, by Application USD Million (2015-2020)
  • Table 40. Asia Pacific Oocyte Cryopreservation, by Component USD Million (2015-2020)
  • Table 41. Asia Pacific Oocyte Cryopreservation, by End User USD Million (2015-2020)
  • Table 42. China Oocyte Cryopreservation, by Type USD Million (2015-2020)
  • Table 43. China Oocyte Cryopreservation, by Application USD Million (2015-2020)
  • Table 44. China Oocyte Cryopreservation, by Component USD Million (2015-2020)
  • Table 45. China Oocyte Cryopreservation, by End User USD Million (2015-2020)
  • Table 46. Japan Oocyte Cryopreservation, by Type USD Million (2015-2020)
  • Table 47. Japan Oocyte Cryopreservation, by Application USD Million (2015-2020)
  • Table 48. Japan Oocyte Cryopreservation, by Component USD Million (2015-2020)
  • Table 49. Japan Oocyte Cryopreservation, by End User USD Million (2015-2020)
  • Table 50. India Oocyte Cryopreservation, by Type USD Million (2015-2020)
  • Table 51. India Oocyte Cryopreservation, by Application USD Million (2015-2020)
  • Table 52. India Oocyte Cryopreservation, by Component USD Million (2015-2020)
  • Table 53. India Oocyte Cryopreservation, by End User USD Million (2015-2020)
  • Table 54. South Korea Oocyte Cryopreservation, by Type USD Million (2015-2020)
  • Table 55. South Korea Oocyte Cryopreservation, by Application USD Million (2015-2020)
  • Table 56. South Korea Oocyte Cryopreservation, by Component USD Million (2015-2020)
  • Table 57. South Korea Oocyte Cryopreservation, by End User USD Million (2015-2020)
  • Table 58. Taiwan Oocyte Cryopreservation, by Type USD Million (2015-2020)
  • Table 59. Taiwan Oocyte Cryopreservation, by Application USD Million (2015-2020)
  • Table 60. Taiwan Oocyte Cryopreservation, by Component USD Million (2015-2020)
  • Table 61. Taiwan Oocyte Cryopreservation, by End User USD Million (2015-2020)
  • Table 62. Australia Oocyte Cryopreservation, by Type USD Million (2015-2020)
  • Table 63. Australia Oocyte Cryopreservation, by Application USD Million (2015-2020)
  • Table 64. Australia Oocyte Cryopreservation, by Component USD Million (2015-2020)
  • Table 65. Australia Oocyte Cryopreservation, by End User USD Million (2015-2020)
  • Table 66. Rest of Asia-Pacific Oocyte Cryopreservation, by Type USD Million (2015-2020)
  • Table 67. Rest of Asia-Pacific Oocyte Cryopreservation, by Application USD Million (2015-2020)
  • Table 68. Rest of Asia-Pacific Oocyte Cryopreservation, by Component USD Million (2015-2020)
  • Table 69. Rest of Asia-Pacific Oocyte Cryopreservation, by End User USD Million (2015-2020)
  • Table 70. Europe Oocyte Cryopreservation, by Country USD Million (2015-2020)
  • Table 71. Europe Oocyte Cryopreservation, by Type USD Million (2015-2020)
  • Table 72. Europe Oocyte Cryopreservation, by Application USD Million (2015-2020)
  • Table 73. Europe Oocyte Cryopreservation, by Component USD Million (2015-2020)
  • Table 74. Europe Oocyte Cryopreservation, by End User USD Million (2015-2020)
  • Table 75. Germany Oocyte Cryopreservation, by Type USD Million (2015-2020)
  • Table 76. Germany Oocyte Cryopreservation, by Application USD Million (2015-2020)
  • Table 77. Germany Oocyte Cryopreservation, by Component USD Million (2015-2020)
  • Table 78. Germany Oocyte Cryopreservation, by End User USD Million (2015-2020)
  • Table 79. France Oocyte Cryopreservation, by Type USD Million (2015-2020)
  • Table 80. France Oocyte Cryopreservation, by Application USD Million (2015-2020)
  • Table 81. France Oocyte Cryopreservation, by Component USD Million (2015-2020)
  • Table 82. France Oocyte Cryopreservation, by End User USD Million (2015-2020)
  • Table 83. Italy Oocyte Cryopreservation, by Type USD Million (2015-2020)
  • Table 84. Italy Oocyte Cryopreservation, by Application USD Million (2015-2020)
  • Table 85. Italy Oocyte Cryopreservation, by Component USD Million (2015-2020)
  • Table 86. Italy Oocyte Cryopreservation, by End User USD Million (2015-2020)
  • Table 87. United Kingdom Oocyte Cryopreservation, by Type USD Million (2015-2020)
  • Table 88. United Kingdom Oocyte Cryopreservation, by Application USD Million (2015-2020)
  • Table 89. United Kingdom Oocyte Cryopreservation, by Component USD Million (2015-2020)
  • Table 90. United Kingdom Oocyte Cryopreservation, by End User USD Million (2015-2020)
  • Table 91. Netherlands Oocyte Cryopreservation, by Type USD Million (2015-2020)
  • Table 92. Netherlands Oocyte Cryopreservation, by Application USD Million (2015-2020)
  • Table 93. Netherlands Oocyte Cryopreservation, by Component USD Million (2015-2020)
  • Table 94. Netherlands Oocyte Cryopreservation, by End User USD Million (2015-2020)
  • Table 95. Rest of Europe Oocyte Cryopreservation, by Type USD Million (2015-2020)
  • Table 96. Rest of Europe Oocyte Cryopreservation, by Application USD Million (2015-2020)
  • Table 97. Rest of Europe Oocyte Cryopreservation, by Component USD Million (2015-2020)
  • Table 98. Rest of Europe Oocyte Cryopreservation, by End User USD Million (2015-2020)
  • Table 99. MEA Oocyte Cryopreservation, by Country USD Million (2015-2020)
  • Table 100. MEA Oocyte Cryopreservation, by Type USD Million (2015-2020)
  • Table 101. MEA Oocyte Cryopreservation, by Application USD Million (2015-2020)
  • Table 102. MEA Oocyte Cryopreservation, by Component USD Million (2015-2020)
  • Table 103. MEA Oocyte Cryopreservation, by End User USD Million (2015-2020)
  • Table 104. Middle East Oocyte Cryopreservation, by Type USD Million (2015-2020)
  • Table 105. Middle East Oocyte Cryopreservation, by Application USD Million (2015-2020)
  • Table 106. Middle East Oocyte Cryopreservation, by Component USD Million (2015-2020)
  • Table 107. Middle East Oocyte Cryopreservation, by End User USD Million (2015-2020)
  • Table 108. Africa Oocyte Cryopreservation, by Type USD Million (2015-2020)
  • Table 109. Africa Oocyte Cryopreservation, by Application USD Million (2015-2020)
  • Table 110. Africa Oocyte Cryopreservation, by Component USD Million (2015-2020)
  • Table 111. Africa Oocyte Cryopreservation, by End User USD Million (2015-2020)
  • Table 112. North America Oocyte Cryopreservation, by Country USD Million (2015-2020)
  • Table 113. North America Oocyte Cryopreservation, by Type USD Million (2015-2020)
  • Table 114. North America Oocyte Cryopreservation, by Application USD Million (2015-2020)
  • Table 115. North America Oocyte Cryopreservation, by Component USD Million (2015-2020)
  • Table 116. North America Oocyte Cryopreservation, by End User USD Million (2015-2020)
  • Table 117. United States Oocyte Cryopreservation, by Type USD Million (2015-2020)
  • Table 118. United States Oocyte Cryopreservation, by Application USD Million (2015-2020)
  • Table 119. United States Oocyte Cryopreservation, by Component USD Million (2015-2020)
  • Table 120. United States Oocyte Cryopreservation, by End User USD Million (2015-2020)
  • Table 121. Canada Oocyte Cryopreservation, by Type USD Million (2015-2020)
  • Table 122. Canada Oocyte Cryopreservation, by Application USD Million (2015-2020)
  • Table 123. Canada Oocyte Cryopreservation, by Component USD Million (2015-2020)
  • Table 124. Canada Oocyte Cryopreservation, by End User USD Million (2015-2020)
  • Table 125. Mexico Oocyte Cryopreservation, by Type USD Million (2015-2020)
  • Table 126. Mexico Oocyte Cryopreservation, by Application USD Million (2015-2020)
  • Table 127. Mexico Oocyte Cryopreservation, by Component USD Million (2015-2020)
  • Table 128. Mexico Oocyte Cryopreservation, by End User USD Million (2015-2020)
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Oocyte Cryopreservation: by Type(USD Million)
  • Table 140. Oocyte Cryopreservation Slow-cooling Method , by Region USD Million (2021-2026)
  • Table 141. Oocyte Cryopreservation Flash-freezing Process (Vitrification) , by Region USD Million (2021-2026)
  • Table 142. Oocyte Cryopreservation: by Application(USD Million)
  • Table 143. Oocyte Cryopreservation 25-30-Year-Old Female , by Region USD Million (2021-2026)
  • Table 144. Oocyte Cryopreservation 30-35-Year-Old Female , by Region USD Million (2021-2026)
  • Table 145. Oocyte Cryopreservation 35-40-Year-Old Female , by Region USD Million (2021-2026)
  • Table 146. Oocyte Cryopreservation Others , by Region USD Million (2021-2026)
  • Table 147. Oocyte Cryopreservation: by Component(USD Million)
  • Table 148. Oocyte Cryopreservation Cryopreservation Media , by Region USD Million (2021-2026)
  • Table 149. Oocyte Cryopreservation Cryopreservation Storage Devices (Dewars, Cryogenic Liquid Cylinders, Cryogenic Storage Tanks, and Storage Container) , by Region USD Million (2021-2026)
  • Table 150. Oocyte Cryopreservation Consumables & Accessories , by Region USD Million (2021-2026)
  • Table 151. Oocyte Cryopreservation Cryo-Shipping , by Region USD Million (2021-2026)
  • Table 152. Oocyte Cryopreservation: by End User(USD Million)
  • Table 153. Oocyte Cryopreservation Biobanks , by Region USD Million (2021-2026)
  • Table 154. Oocyte Cryopreservation IVF & Fertility Clinics , by Region USD Million (2021-2026)
  • Table 155. Oocyte Cryopreservation Research & Academic Institutes , by Region USD Million (2021-2026)
  • Table 156. Oocyte Cryopreservation Cryo-shipping/couriers , by Region USD Million (2021-2026)
  • Table 157. Oocyte Cryopreservation Cryo Monitoring /Inventory Management , by Region USD Million (2021-2026)
  • Table 158. South America Oocyte Cryopreservation, by Country USD Million (2021-2026)
  • Table 159. South America Oocyte Cryopreservation, by Type USD Million (2021-2026)
  • Table 160. South America Oocyte Cryopreservation, by Application USD Million (2021-2026)
  • Table 161. South America Oocyte Cryopreservation, by Component USD Million (2021-2026)
  • Table 162. South America Oocyte Cryopreservation, by End User USD Million (2021-2026)
  • Table 163. Brazil Oocyte Cryopreservation, by Type USD Million (2021-2026)
  • Table 164. Brazil Oocyte Cryopreservation, by Application USD Million (2021-2026)
  • Table 165. Brazil Oocyte Cryopreservation, by Component USD Million (2021-2026)
  • Table 166. Brazil Oocyte Cryopreservation, by End User USD Million (2021-2026)
  • Table 167. Argentina Oocyte Cryopreservation, by Type USD Million (2021-2026)
  • Table 168. Argentina Oocyte Cryopreservation, by Application USD Million (2021-2026)
  • Table 169. Argentina Oocyte Cryopreservation, by Component USD Million (2021-2026)
  • Table 170. Argentina Oocyte Cryopreservation, by End User USD Million (2021-2026)
  • Table 171. Rest of South America Oocyte Cryopreservation, by Type USD Million (2021-2026)
  • Table 172. Rest of South America Oocyte Cryopreservation, by Application USD Million (2021-2026)
  • Table 173. Rest of South America Oocyte Cryopreservation, by Component USD Million (2021-2026)
  • Table 174. Rest of South America Oocyte Cryopreservation, by End User USD Million (2021-2026)
  • Table 175. Asia Pacific Oocyte Cryopreservation, by Country USD Million (2021-2026)
  • Table 176. Asia Pacific Oocyte Cryopreservation, by Type USD Million (2021-2026)
  • Table 177. Asia Pacific Oocyte Cryopreservation, by Application USD Million (2021-2026)
  • Table 178. Asia Pacific Oocyte Cryopreservation, by Component USD Million (2021-2026)
  • Table 179. Asia Pacific Oocyte Cryopreservation, by End User USD Million (2021-2026)
  • Table 180. China Oocyte Cryopreservation, by Type USD Million (2021-2026)
  • Table 181. China Oocyte Cryopreservation, by Application USD Million (2021-2026)
  • Table 182. China Oocyte Cryopreservation, by Component USD Million (2021-2026)
  • Table 183. China Oocyte Cryopreservation, by End User USD Million (2021-2026)
  • Table 184. Japan Oocyte Cryopreservation, by Type USD Million (2021-2026)
  • Table 185. Japan Oocyte Cryopreservation, by Application USD Million (2021-2026)
  • Table 186. Japan Oocyte Cryopreservation, by Component USD Million (2021-2026)
  • Table 187. Japan Oocyte Cryopreservation, by End User USD Million (2021-2026)
  • Table 188. India Oocyte Cryopreservation, by Type USD Million (2021-2026)
  • Table 189. India Oocyte Cryopreservation, by Application USD Million (2021-2026)
  • Table 190. India Oocyte Cryopreservation, by Component USD Million (2021-2026)
  • Table 191. India Oocyte Cryopreservation, by End User USD Million (2021-2026)
  • Table 192. South Korea Oocyte Cryopreservation, by Type USD Million (2021-2026)
  • Table 193. South Korea Oocyte Cryopreservation, by Application USD Million (2021-2026)
  • Table 194. South Korea Oocyte Cryopreservation, by Component USD Million (2021-2026)
  • Table 195. South Korea Oocyte Cryopreservation, by End User USD Million (2021-2026)
  • Table 196. Taiwan Oocyte Cryopreservation, by Type USD Million (2021-2026)
  • Table 197. Taiwan Oocyte Cryopreservation, by Application USD Million (2021-2026)
  • Table 198. Taiwan Oocyte Cryopreservation, by Component USD Million (2021-2026)
  • Table 199. Taiwan Oocyte Cryopreservation, by End User USD Million (2021-2026)
  • Table 200. Australia Oocyte Cryopreservation, by Type USD Million (2021-2026)
  • Table 201. Australia Oocyte Cryopreservation, by Application USD Million (2021-2026)
  • Table 202. Australia Oocyte Cryopreservation, by Component USD Million (2021-2026)
  • Table 203. Australia Oocyte Cryopreservation, by End User USD Million (2021-2026)
  • Table 204. Rest of Asia-Pacific Oocyte Cryopreservation, by Type USD Million (2021-2026)
  • Table 205. Rest of Asia-Pacific Oocyte Cryopreservation, by Application USD Million (2021-2026)
  • Table 206. Rest of Asia-Pacific Oocyte Cryopreservation, by Component USD Million (2021-2026)
  • Table 207. Rest of Asia-Pacific Oocyte Cryopreservation, by End User USD Million (2021-2026)
  • Table 208. Europe Oocyte Cryopreservation, by Country USD Million (2021-2026)
  • Table 209. Europe Oocyte Cryopreservation, by Type USD Million (2021-2026)
  • Table 210. Europe Oocyte Cryopreservation, by Application USD Million (2021-2026)
  • Table 211. Europe Oocyte Cryopreservation, by Component USD Million (2021-2026)
  • Table 212. Europe Oocyte Cryopreservation, by End User USD Million (2021-2026)
  • Table 213. Germany Oocyte Cryopreservation, by Type USD Million (2021-2026)
  • Table 214. Germany Oocyte Cryopreservation, by Application USD Million (2021-2026)
  • Table 215. Germany Oocyte Cryopreservation, by Component USD Million (2021-2026)
  • Table 216. Germany Oocyte Cryopreservation, by End User USD Million (2021-2026)
  • Table 217. France Oocyte Cryopreservation, by Type USD Million (2021-2026)
  • Table 218. France Oocyte Cryopreservation, by Application USD Million (2021-2026)
  • Table 219. France Oocyte Cryopreservation, by Component USD Million (2021-2026)
  • Table 220. France Oocyte Cryopreservation, by End User USD Million (2021-2026)
  • Table 221. Italy Oocyte Cryopreservation, by Type USD Million (2021-2026)
  • Table 222. Italy Oocyte Cryopreservation, by Application USD Million (2021-2026)
  • Table 223. Italy Oocyte Cryopreservation, by Component USD Million (2021-2026)
  • Table 224. Italy Oocyte Cryopreservation, by End User USD Million (2021-2026)
  • Table 225. United Kingdom Oocyte Cryopreservation, by Type USD Million (2021-2026)
  • Table 226. United Kingdom Oocyte Cryopreservation, by Application USD Million (2021-2026)
  • Table 227. United Kingdom Oocyte Cryopreservation, by Component USD Million (2021-2026)
  • Table 228. United Kingdom Oocyte Cryopreservation, by End User USD Million (2021-2026)
  • Table 229. Netherlands Oocyte Cryopreservation, by Type USD Million (2021-2026)
  • Table 230. Netherlands Oocyte Cryopreservation, by Application USD Million (2021-2026)
  • Table 231. Netherlands Oocyte Cryopreservation, by Component USD Million (2021-2026)
  • Table 232. Netherlands Oocyte Cryopreservation, by End User USD Million (2021-2026)
  • Table 233. Rest of Europe Oocyte Cryopreservation, by Type USD Million (2021-2026)
  • Table 234. Rest of Europe Oocyte Cryopreservation, by Application USD Million (2021-2026)
  • Table 235. Rest of Europe Oocyte Cryopreservation, by Component USD Million (2021-2026)
  • Table 236. Rest of Europe Oocyte Cryopreservation, by End User USD Million (2021-2026)
  • Table 237. MEA Oocyte Cryopreservation, by Country USD Million (2021-2026)
  • Table 238. MEA Oocyte Cryopreservation, by Type USD Million (2021-2026)
  • Table 239. MEA Oocyte Cryopreservation, by Application USD Million (2021-2026)
  • Table 240. MEA Oocyte Cryopreservation, by Component USD Million (2021-2026)
  • Table 241. MEA Oocyte Cryopreservation, by End User USD Million (2021-2026)
  • Table 242. Middle East Oocyte Cryopreservation, by Type USD Million (2021-2026)
  • Table 243. Middle East Oocyte Cryopreservation, by Application USD Million (2021-2026)
  • Table 244. Middle East Oocyte Cryopreservation, by Component USD Million (2021-2026)
  • Table 245. Middle East Oocyte Cryopreservation, by End User USD Million (2021-2026)
  • Table 246. Africa Oocyte Cryopreservation, by Type USD Million (2021-2026)
  • Table 247. Africa Oocyte Cryopreservation, by Application USD Million (2021-2026)
  • Table 248. Africa Oocyte Cryopreservation, by Component USD Million (2021-2026)
  • Table 249. Africa Oocyte Cryopreservation, by End User USD Million (2021-2026)
  • Table 250. North America Oocyte Cryopreservation, by Country USD Million (2021-2026)
  • Table 251. North America Oocyte Cryopreservation, by Type USD Million (2021-2026)
  • Table 252. North America Oocyte Cryopreservation, by Application USD Million (2021-2026)
  • Table 253. North America Oocyte Cryopreservation, by Component USD Million (2021-2026)
  • Table 254. North America Oocyte Cryopreservation, by End User USD Million (2021-2026)
  • Table 255. United States Oocyte Cryopreservation, by Type USD Million (2021-2026)
  • Table 256. United States Oocyte Cryopreservation, by Application USD Million (2021-2026)
  • Table 257. United States Oocyte Cryopreservation, by Component USD Million (2021-2026)
  • Table 258. United States Oocyte Cryopreservation, by End User USD Million (2021-2026)
  • Table 259. Canada Oocyte Cryopreservation, by Type USD Million (2021-2026)
  • Table 260. Canada Oocyte Cryopreservation, by Application USD Million (2021-2026)
  • Table 261. Canada Oocyte Cryopreservation, by Component USD Million (2021-2026)
  • Table 262. Canada Oocyte Cryopreservation, by End User USD Million (2021-2026)
  • Table 263. Mexico Oocyte Cryopreservation, by Type USD Million (2021-2026)
  • Table 264. Mexico Oocyte Cryopreservation, by Application USD Million (2021-2026)
  • Table 265. Mexico Oocyte Cryopreservation, by Component USD Million (2021-2026)
  • Table 266. Mexico Oocyte Cryopreservation, by End User USD Million (2021-2026)
  • Table 267. Research Programs/Design for This Report
  • Table 268. Key Data Information from Secondary Sources
  • Table 269. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Oocyte Cryopreservation: by Type USD Million (2015-2020)
  • Figure 5. Global Oocyte Cryopreservation: by Application USD Million (2015-2020)
  • Figure 6. Global Oocyte Cryopreservation: by Component USD Million (2015-2020)
  • Figure 7. Global Oocyte Cryopreservation: by End User USD Million (2015-2020)
  • Figure 8. South America Oocyte Cryopreservation Share (%), by Country
  • Figure 9. Asia Pacific Oocyte Cryopreservation Share (%), by Country
  • Figure 10. Europe Oocyte Cryopreservation Share (%), by Country
  • Figure 11. MEA Oocyte Cryopreservation Share (%), by Country
  • Figure 12. North America Oocyte Cryopreservation Share (%), by Country
  • Figure 13. Global Oocyte Cryopreservation share by Players 2020 (%)
  • Figure 14. Global Oocyte Cryopreservation share by Players (Top 3) 2020(%)
  • Figure 15. Global Oocyte Cryopreservation share by Players (Top 5) 2020(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Anova Fertility (Canada) Revenue, Net Income and Gross profit
  • Figure 18. Anova Fertility (Canada) Revenue: by Geography 2020
  • Figure 19. Manchester Fertility (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 20. Manchester Fertility (United Kingdom) Revenue: by Geography 2020
  • Figure 21. CCRM IVF (United States) Revenue, Net Income and Gross profit
  • Figure 22. CCRM IVF (United States) Revenue: by Geography 2020
  • Figure 23. CREATE Fertility (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 24. CREATE Fertility (United Kingdom) Revenue: by Geography 2020
  • Figure 25. Extend Fertility (United States) Revenue, Net Income and Gross profit
  • Figure 26. Extend Fertility (United States) Revenue: by Geography 2020
  • Figure 27. Kindbody (United States) Revenue, Net Income and Gross profit
  • Figure 28. Kindbody (United States) Revenue: by Geography 2020
  • Figure 29. HRC Fertility (United States) Revenue, Net Income and Gross profit
  • Figure 30. HRC Fertility (United States) Revenue: by Geography 2020
  • Figure 31. London Women's Clinic (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 32. London Women's Clinic (United Kingdom) Revenue: by Geography 2020
  • Figure 33. IVF Australia (Australia) Revenue, Net Income and Gross profit
  • Figure 34. IVF Australia (Australia) Revenue: by Geography 2020
  • Figure 35. Prelude Fertility (United States) Revenue, Net Income and Gross profit
  • Figure 36. Prelude Fertility (United States) Revenue: by Geography 2020
  • Figure 37. Global Oocyte Cryopreservation: by Type USD Million (2021-2026)
  • Figure 38. Global Oocyte Cryopreservation: by Application USD Million (2021-2026)
  • Figure 39. Global Oocyte Cryopreservation: by Component USD Million (2021-2026)
  • Figure 40. Global Oocyte Cryopreservation: by End User USD Million (2021-2026)
  • Figure 41. South America Oocyte Cryopreservation Share (%), by Country
  • Figure 42. Asia Pacific Oocyte Cryopreservation Share (%), by Country
  • Figure 43. Europe Oocyte Cryopreservation Share (%), by Country
  • Figure 44. MEA Oocyte Cryopreservation Share (%), by Country
  • Figure 45. North America Oocyte Cryopreservation Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Anova Fertility (Canada)
  • Manchester Fertility (United Kingdom)
  • CCRM IVF (United States)
  • CREATE Fertility (United Kingdom)
  • Extend Fertility (United States)
  • Kindbody (United States)
  • HRC Fertility (United States)
  • London Women's Clinic (United Kingdom)
  • IVF Australia (Australia)
  • Prelude Fertility (United States)
Additional players considered in the study are as follows:
Reproductive Biology Associates (United States) , Virtus Health (Australia) , Mayo Clinic (United States) , Pacific Fertility Center-Los Angeles (PFCLA) (United States) , Monash IVF (Australia) , Shady Grove Fertility (United States) , Melbourne IVF (Australia) , San Diego Fertility Center (SDFC) (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation